Insider · CIK 0001835498
Ronald Kirk Huntsman
Files at VVOS (Vivos Therapeutics, Inc.). First filing -, latest -.
Ronald Kirk Huntsman files SEC Form 4 as CEO and director at VVOS (Vivos Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Ronald Kirk Huntsman has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | VVOS Vivos Therapeutics, Inc. | JOther Preferred Stockindirect: See footnote | +85,910 | $0.58 | $50k | 85,910 | 25 d ago |
| Jun 30, 2026 | VVOS Vivos Therapeutics, Inc. | JOther Warrant (Right to Buy)derivativeindirect: See footnote | +85,910 | $0.58 | $50k | 85,910 | 25 d ago |
| Nov 26, 2024 | VVOS Vivos Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +315,421 | $2.64 | $833k | 364,755 | Nov 27, 2024 |
Questions about Ronald Kirk Huntsman
Answered from the filings on this page, as of the latest one.
Is Ronald Kirk Huntsman buying or selling?
Ronald Kirk Huntsman has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Ronald Kirk Huntsman's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ronald Kirk Huntsman has 0.
Where does Ronald Kirk Huntsman file Form 4?
Ronald Kirk Huntsman has filed Form 4 at VVOS (Vivos Therapeutics, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.